Polypeptide for targeted inhibition of TRIB3 and its use
By developing polypeptides that specifically bind TRIB3 protein, block their interaction with GSK-3β, inhibit macrophage activation, solve the problem of pulmonary fibrosis treatment, significantly improve lung function and efficacy, and provide an effective treatment Drugs for pulmonary fibrosis.
Patent Information
- Application Number
- CN202111504956.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-10
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-12-10
Smart Images

Figure BDA0003402903450000091 
Figure BDA0003402903450000092 
Figure BDA0003402903450000101
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a polypeptide and a polypeptide derivative thereof and application thereof in preparing a medicine for treating pulmonary fibrosis. Background Art
[0002] Pulmonary fibrosis is a terminal change of a large class of lung diseases characterized by fibroblast proliferation and accumulation of a large amount of extracellular matrix accompanied by inflammatory damage and tissue structure destruction. It is one of the four major types of respiratory diseases and the most serious pathological state of the lungs. Its pathological changes are mostly manifested as initial lower respiratory tract inflammation, as well as damage to alveolar epithelial cells and vascular endothelial cells, accompanied by proliferation of fibroblasts and type II alveolar cells, cytokine release, deposition of extracellular matrix proteins and collagen, and ultimately causing lung changes. In patients with pulmonary fibrosis, the alveoli of the lungs are gradually replaced by fibrous substances, causing the lung tissue to become hard and thick, and the gas exchange capacity of the lungs is gradually lost, resulting in varying degrees of hypoxia and dyspnea in patients, and finally death from respiratory failure. The etiology of pulmonary fibrosis is complex and the pathogenesis is unknown. The existing drugs and methods for the treatment of pulmonary fibrosis are very limited, and the efficacy is unsatisfactory. The prognosis is extremely poor, and the 5-year survival rate is only 50%.
[0003] TRIB3 (Tribbles Homologue 3) is a member of the Tribbles homologue protein family. It was first identified in Drosophila and was found to inhibit mitosis and regulate cell proliferation, migration and morphogenesis during development. In mammals, there are three Tribbles homologue proteins: TRIB1, TRIB2 and TRIB3, all of which are members of the pseudokinase protein family. All three proteins contain Ser / Thr protein kinase-like domains (Kinase Ilike Idomain, KD), but lack ATP binding sites and catalytic residues, and therefore have no kinase activity. Despite this, Tribbles proteins have adaptor protein-like functions and participate in the assembly of multiple protein complexes. Among the mammalian Tribbles family members, TRIB3 has been studied most intensively, and its interacting proteins include transcription factors, ubiquitin ligases, type II BMP receptors on the cell membrane, and members of the MAPK and PI3K signaling pathways. By interacting with these proteins, TRIB3 is involved in the regulation of glucose and lipid metabolism, adipocyte differentiation, apoptosis, stress and collagen expression.
[0004] Recent research evidence shows that TRIB3 plays an important regulatory role in the occurrence and development of tissue fibrosis. For example, TRIB3 plays a profibrotic role in renal tissue and systemic sclerosis by activating TGF-1 signaling. Stress-induced TRIB3 promotes the release of exosomes from hepatocytes and activates hepatic stellate cells by affecting the cargo function of SQSTM1, thereby promoting the progression of liver fibrosis.
[0005] The preliminary results of the present invention show that persistent and repeated lung damage promotes high expression of TRIB3 in alveolar macrophages, and the highly expressed TRIB3 interacts with GSK-3β, increases the interaction between GSK-3β and A20, induces A20 phosphorylation, inhibits A20 enzyme activity, leads to activation of alveolar macrophages, and then secretes a large amount of pro-fibrotic factors to promote the proliferation, migration and activation of lung fibroblasts (the main effector cells of pulmonary fibrosis). These results suggest that targeting the interaction between TRIB3 and GSK-3β is a potential target for the treatment of tissue fibrosis. Therefore, research and development of substances that block the interaction between TRIB3 and GSK-3β proteins has a good prospect for the development of drugs for the treatment of tissue fibrosis. Summary of the invention
[0006] The technical problem solved by the present invention is that the pathogenesis of pulmonary fibrosis is complex and there is a lack of effective therapeutic drugs. A polypeptide is provided that inhibits macrophage activation by interrupting the interaction between TRIB3 and GSK-3β, and its application in the preparation of products for the treatment of pulmonary fibrosis. The amino acid sequence of the polypeptide PG is shown in SEQ ID NO: 1.
[0007] The amino acid sequence of the present invention also includes oligopeptide sequences that have amino acid substitutions, deletions or additions at other positions and can specifically bind to TRIB3. The polypeptide of the present invention and its derivatives are used for targeted treatment of diseases related to TRIB3.
[0008] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions.
[0009] The first aspect of the technical solution of the present invention is to provide a polypeptide and its polypeptide derivatives that can specifically bind to TRIB3 and target the inhibition of GSK-3β's macrophage activation effect, characterized in that the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO.1, or a sequence with the same function obtained by replacing, deleting or adding amino acids at any position thereof; the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide with a cell-penetrating peptide (a cell-penetrating peptide is a type of short peptide that can carry macromolecules into cells, and its membrane-penetrating ability does not rely on classical endocytosis).
[0010] The cell-penetrating peptide is HLYVSPW (as shown in SEQ ID NO: 2 in the sequence table), and the cell-penetrating peptide is named pep2. Furthermore, the N-terminus or C-terminus of the polypeptide PG is connected to the cell-penetrating peptide to obtain the chimeric peptide.
[0011] The second aspect of the technical solution of the present invention is to provide the use of the polypeptide and its polypeptide derivatives described in the first aspect of the technical solution of the present invention in the preparation of drugs for targeted inhibition of the macrophage activation effect of GSK-3β, and in the preparation of drugs for treating pulmonary fibrosis. The "pulmonary fibrosis" described in the present invention is conventional pulmonary fibrosis in the art. The pulmonary fibrosis preferably refers to pulmonary fibrosis caused by various factors and characterized by pathological changes of idiopathic pulmonary fibrosis. The pulmonary fibrosis preferably refers to pulmonary fibrosis of humans or animals, and the symptoms of pulmonary fibrosis more preferably include: pulmonary inflammation caused by pulmonary fibrosis, and lung function deterioration caused by pulmonary fibrosis. The cause of pulmonary fibrosis is preferably: pulmonary fibrosis caused by lung damage, pulmonary fibrosis caused by dust, or pulmonary fibrosis caused by drugs, wherein the drug is preferably bleomycin.
[0012] The pulmonary fibrosis is preferably primary (specific) pulmonary fibrosis, i.e. pulmonary fibrosis of unknown cause; or secondary pulmonary fibrosis, i.e. pulmonary fibrosis secondary to a previous disease, and the pulmonary fibrosis is more preferably pulmonary function degeneration, pulmonary inflammation and lung damage in pulmonary fibrosis. The pulmonary fibrosis disease preferably includes chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis or interstitial pneumonia.
[0013] The term "treatment" as used in the present invention refers to reducing the degree of pulmonary fibrosis, or curing pulmonary fibrosis to normalize it, or slowing down the progression of pulmonary fibrosis.
[0014] The polypeptide or chimera of the present invention can be used as an active ingredient to prepare an anti-pulmonary fibrosis drug. The "active ingredient" refers to a compound that has the function of treating pulmonary fibrosis. The polypeptide or chimera can be used with one or more pharmaceutical carriers to prepare an anti-pulmonary fibrosis drug. In the drug, the polypeptide or chimera can be used alone as an active ingredient or together with other compounds with anti-pulmonary fibrosis activity as an active ingredient. The pharmaceutical carrier is a conventional pharmaceutical carrier in the art, preferably including pharmaceutically acceptable excipients, fillers, diluents, etc.
[0015] The drug for treating pulmonary fibrosis is preferably a pharmaceutical composition, and the dosage form of the pharmaceutical composition is not particularly limited and is a conventional dosage form in the art. The dosage form of the pharmaceutical composition is preferably solid, semisolid or liquid. The dosage form of the pharmaceutical composition can also be an aqueous solution, a non-aqueous solution or a suspension. The dosage form of the pharmaceutical composition is more preferably a tablet, a capsule, a granule, an injection or an infusion. The administration route of the pharmaceutical composition is a conventional administration route in the art, and the administration route is preferably injection or oral administration. The injection administration method preferably includes: intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection.
[0016] The dosage of the pharmaceutical composition of the present invention during treatment depends on the age and condition of the patient, and is preferably 0.1-15 mg / kg, more preferably 5-10 mg / kg, preferably 5 mg / kg, and the administration frequency is preferably once or several times a day. In the treatment of pulmonary fibrosis, the pharmaceutical composition of the present invention can be used alone or in combination with other drugs.
[0017] Furthermore, the pulmonary fibrosis includes primary pulmonary fibrosis or secondary pulmonary fibrosis.
[0018] Furthermore, the pulmonary fibrosis is drug-induced pulmonary fibrosis.
[0019] Furthermore, the drug-induced pulmonary fibrosis is drug-induced pulmonary fibrosis caused by bleomycin.
[0020] Furthermore, the product treats pulmonary fibrosis by treating lung inflammation, lung function deterioration or lung damage.
[0021] Beneficial technical effects: The present invention provides a polypeptide that can specifically bind to TRIB3, which can target and block the interaction between TRIB3 and GSK-3β, restore A20 enzyme activity, and inhibit the profibrotic phenotype of macrophages, thereby being applied to the preparation of drugs against pulmonary fibrosis. The drugs prepared using the above polypeptides have the advantages of significant efficacy, low toxicity and side effects, and safe use in the treatment of pulmonary fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The results of immunoprecipitation in Example 3 to verify the binding of TRIB3 and protein GSK-3β in alveolar macrophages; wherein A is the protein content of GSK-3β protein and TRIB3 protein contained in the initial alveolar macrophage lysate; B is the protein content of TRIB3 protein and GSK-3β protein contained in the alveolar macrophage lysate after precipitation with GSK-3β antibody or control antibody IgG;
[0023] Figure 2This is the pathological picture of Sirius red special staining in Example 7. DETAILED DESCRIPTION
[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0025] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0026] The reagents and raw materials used in the present invention are commercially available.
[0027] The PBS described in the examples refers to a phosphate buffer with a concentration of 0.1 M and a pH value of 7.2.
[0028] The room temperature described in the examples is the conventional room temperature in the art, preferably 15-30°C.
[0029] The experimental results are expressed as mean ± standard error. After comparison with parametric or non-parametric variance test, p < 0.05 is considered to be significantly different, and p < 0.01 is considered to be extremely significantly different.
[0030] Example 1 Preparation of animal model of pulmonary fibrosis
[0031] 1.1 Main reagents and experimental animals
[0032] The bleomycin used in the experiment was purchased from Nippon Kayaku, batch number X81040.
[0033] Unless otherwise specified, all compounds used in the experiments were purchased from Sigma.
[0034] The SPF-grade C57BL / 6 mice (male, 6-8 weeks old, 16-18 g) used in the experiment were purchased from the Institute of Animal Science, Chinese Academy of Medical Sciences.
[0035] 1.2 Preparation of animal model of pulmonary fibrosis
[0036] Male C57BL / 6 mice (6-8 weeks old) were fasted overnight, anesthetized with sodium pentobarbital (45 mg / kg, ip), and injected with bleomycin (3 U / kg) intratracheally.
[0037] The specific plan is: cut the neck skin with minimal trauma, expose the trachea with the help of elbow ophthalmic forceps, puncture the trachea with a microinjector, inject about 50 μL of bleomycin into the trachea, and quickly rotate and stand upright for 5 minutes to allow bleomycin to evenly enter the left and right lung lobes. The entire operation was performed on a surgical operating table at about 60°C. The sham operation group was injected with an equal amount of injection saline into the trachea.
[0038] Example 2 Detection of TRIB3 protein expression in alveolar macrophages of mice with pulmonary fibrosis by Western blot
[0039] Take an appropriate amount of alveolar macrophages from the animal model prepared in Example 1, add lysis buffer [containing 0.1mM EDTA (ethylenediaminetetraacetic acid), 0.1mM EGTA (ethylene glycol diethyl ether diaminetetraacetic acid), 10mM KCl (potassium chloride) and 10mM HEPEs (4-hydroxyethylpiperazineethanesulfonic acid) and 50mM NaF (sodium fluoride), 0.1M Na3VO4 (sodium vanadate), 0.1M Na3PO4 (sodium pyrophosphate), protease inhibitors 1mmol / L Aprotinin (protease inhibitor), Trypsin inhibitor (trypsin inhibitor), PMSF (phenylmethylsulfonyl fluoride), Leupeptins (leupeptin) and DTT (dithiothreitol)] and homogenize, place on ice for 15min, shake occasionally. Quickly add 10% NP-40 and mix well, centrifuge at 4°C, 12000rpm for 5min. The supernatant was taken, and the protein concentration was determined by the Coomassie brilliant blue method. The protein concentration was adjusted to the same for Western Blot analysis to detect TRIB3. Amersham colorimetric solution (NBT / BCIP staining kit IK5030 of Huamei Company) was used for color development, and the optical density value of each band was measured by Western-blot analysis software (gelPro32). The results are shown in Table 1. The results in Table 1 show that TRIB3 protein is highly expressed in the lung tissue of mice with pulmonary fibrosis.
[0040] Table 1 Increased expression of TRIB3 in alveolar macrophages of mice with pulmonary fibrosis
[0041] Protein name Sham operation group Model Group P-value TRIB3 expression in alveolar macrophages 17593.34 46111.44 0.00708
[0042] Example 3: Verification of the binding of TRIB3 and protein GSK-3β in alveolar macrophages by immunoprecipitation
[0043] 3.1 Immunoprecipitation reagents
[0044] Lysis buffer A: 0.6057 g Tris base, 1.7532 g NaCl, 0.1017 g MgCl2·6H2O, 0.0742 g EDTA, 10 mL glycerol, 10 mL 10% NP40, add deionized water to 150 mL, adjust the pH to 7.6 with HCl, make up to 191 mL, mix well, filter through 0.45 μm filter membrane, and store at 4°C.
[0045] Lysis buffer B: 200 μL 2M β-glycerophosphate, 4 mL 2.5M NaF, 2 mL 100 mM NaVO 3 , 2mL 100mMPMSF, 20μL 1M DTT, 200μL each of 1mg / mL Leu, Pep, and Apr, total volume 9mL. The mother solution is stored at -20℃. Before use, thaw the mother solution of each component in solution B, add them to solution A according to the above composition ratio and mix well.
[0046] Protein A / G Plus-Agarose was purchased from Santa cruz Company, USA.
[0047] 3.2 Specific operation steps
[0048] (1) Alveolar macrophages were obtained from the bronchoalveolar lavage fluid of mice.
[0049] (2) Lyse the cells with immunoprecipitation lysis buffer, harvest about 4-10 mg of total cell protein, and adjust each group of proteins to the same concentration. Take 200 μg of each group of proteins and take 200 μg of each group of proteins as the input group of cell lysate, and use the obtained input group of cell lysate as the control.
[0050] (3) Add 2 μg of GSK-3β antibody (purchased from CST, No. 9315) or common IgG antibody of the same species as GSK-3β antibody (purchased from cell signaling, product No. 2729) to the remaining protein, and add 10 μL of ProteinA / G Plus-Agarose to fully resuspend, and slowly rotate and shake at 4°C overnight. Centrifuge at 4°C, 3000 rpm for 5 min, and carefully remove the supernatant. It is better to leave a small amount of supernatant than to remove the Agarose. Add 0.5 mL of immunoprecipitation lysis buffer, mix well, stand for 1 min in an ice bath, centrifuge at 4°C, 3000 rpm for 30 sec, and carefully remove the supernatant. Repeat the washing for 5 times, and stand for 5 min before the last centrifugation. Carefully remove the supernatant, add 50 μL of 2×SDS gel loading buffer, mix well, denature at 95°C for 5 min, and quickly transfer to an ice bath for cooling. Centrifuge at 12000 rpm for 2 min at room temperature. The supernatant is the precipitated protein sample. Take part or all of it for SDS-polyacrylamide gel electrophoresis.
[0051] 3.3 Results
[0052] The results are as follows Figure 1 As shown in (where A shows the protein content of GSK-3β protein and TRIB3 protein contained in the initial alveolar macrophage lysate; B shows the protein amount of TRIB3 protein and GSK-3β protein contained in the alveolar macrophage lysate after precipitation with GSK-3β antibody or control antibody IgG), by Figure 1 The results showed that TRIB3 protein and GSK-3β protein in alveolar macrophages were bound to each other. The preparation method of the input cell lysate was as shown above. The input represented the protein content of TRIB3 and GSK-3β in the initial alveolar macrophage lysate, that is, the GSK-3β and TRIB3 protein content of the protein stock solution before precipitation by GSK-3 antibody or control antibody IgG (since GSK-3β antibody is an IgG antibody, IgG antibody is selected as a control). The results showed that the content of GSK-3β protein and TRIB3 protein in the cell lysate of the input group was consistent.
[0053] The output represents the amount of protein contained in the protein stock solution after precipitation with GSK-3β antibody or control antibody IgG. Since IgG antibody, as the control antibody of GSK-3β antibody, cannot precipitate GSK-3β protein, the GSK-3β protein blot lane in the cell lysate treated with IgG antibody is blank. GSK-3β antibody, as the experimental group antibody, can bind to GSK-3β protein and precipitate it. Therefore, the result of the cell lysate treated with GSK-3β antibody is that the TRIB3 protein blot lane is black. It is precisely because of the interaction between TRIB3 protein and GSK-3β protein that TRIB3 protein can be precipitated when GSK-3β antibody is used to precipitate GSK-3β protein. Therefore, the TRIB3 protein blot lane of the cell lysate treated with GSK-3β antibody is black. Since IgG antibody cannot precipitate GSK-3β protein, it cannot precipitate GSK-3β interacting protein TRIB3, so the TRIB3 protein blot lane of the cell lysate treated with IgG antibody is blank. The above experimental results fully prove that TRIB3 protein and GSK-3β protein can directly interact with each other.
[0054] Example 4 Detection of the binding ability of polypeptide PG and TRIB3 protein using surface plasmon resonance method
[0055] The amino acid sequence of the PG polypeptide is ETVYRVARHYSR (SEQ ID NO: 1).
[0056] The surface plasmon resonance experiment was carried out in a surface plasmon resonance instrument Biacore T200, and the operation steps were carried out according to the instruction manual of the plasma resonance instrument Biacore T200. The specific steps are as follows:
[0057] (1) Purified TRB3 protein (purchased from RD) was coupled to a CM5 chip (purchased from GE) via amino coupling, unbound protein was removed by elution at a flow rate of 10 μL / min, and the chip surface was equilibrated for 2 hours. The specific steps of amino coupling, elution and equilibration refer to the relevant instructions of GE's CM5 chip.
[0058] (2) 250 μL of PG peptide fragments of different concentrations (1000, 500, 250, 125, 62.5, 31.25, 15.625 and 7.8125 nM) were automatically injected, and the entire surface plasmon resonance experiment was carried out at 25°C. The buffer used was HBS-EP buffer [0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA and 0.005% (w / w) surfactant]. The binding curves of peptides of different concentrations with TRIB3 were simulated using the analysis software provided by BiacoreT200, and the affinity of the peptides with TRIB3 protein was calculated. The results are shown in Table 2, which shows that the peptide PG has a higher affinity with the TRIB3 protein.
[0059] Table 2 Affinity test of peptide PG and TRIB3 protein
[0060] Peptide name Affinity constant (KD) for TRB3 protein PG <![CDATA[3.956×10 -8 M]]>
[0061] Example 5 Competitive ELISA method verifies that peptide PG can compete for the binding of TRIB3 and GSK-3β protein
[0062] The specific steps are as follows:
[0063] 1. Dilute human TRIB3 protein and bovine serum albumin (BSA) to 10 μg / mL with PBS, add 100 μL to each well, and coat a 96-well ELISA plate at 4°C overnight.
[0064] 2. Wash three times with PBS containing 0.1% Tween-20. Coat the plate with 200 μL of blocking solution (10% bovine serum PBS) at 37°C for 2 hours.
[0065] 3. Pour off the coating solution, add 100 μL of blocking solution as a control and 100 μL of peptide PG diluted with blocking solution to each well, and incubate at room temperature for 1 hour.
[0066] 4. Wash five times with PBS containing 0.1% Tween-20, add 200 μL of 1 μg / mL GSK-3β-DDK protein solution to each well, and incubate at 37°C for 1 h.
[0067] 5. Wash five times with PBS containing 0.1% Tween-20, add horseradish peroxidase-labeled DDK antibody to each well, and incubate at room temperature for 1 hour.
[0068] 6. Wash six times with PBS containing 0.1% Tween-20. Prepare substrate colorimetric solution (100mmol / L sodium acetate, pH 6.0, add 10μL 30% hydrogen peroxide, 100μg / mL TMB per 50mL buffer), add 100μL to each well, and incubate at room temperature for 5min. Add 50μL 0.1M dilute sulfuric acid to each well to terminate the reaction.
[0069] 7. The results are expressed as OD450 of the sample wells, see Table 3.
[0070] The results showed that PG could compete for the binding of TRIB3 and GSK-3β protein.
[0071] Table 3 Peptides compete for the binding of TRIB3 and GSK-3β protein
[0072] PG (ELISA value) BSA (ELISA value) P-value 0.54 1.67 0.00107 0.62 1.34 0.42 1.65
[0073] Example 6 Peptide PG inhibits macrophage profibrotic phenotype
[0074] The peptide PG was connected to the cell-penetrating peptide Pep2 (sequence: HLYVSPW (SEQ ID NO: 2)) to form a new Pep2-PG (HLYVSPWGGETVYRVARHYSR, SEQ ID NO: 3). This peptide was synthesized by Anhui Guoping Pharmaceutical Co., Ltd. with a purity of >98%.
[0075] The specific steps are as follows:
[0076] 1. Isolate alveolar macrophages from the bronchoalveolar lavage fluid of mice in the model group and inoculate them into 12-well plates.
[0077] 2. After the cells adhered, 10 μM Pep2-PG or control peptide was added to the cells.
[0078] 3. After 12 hours, cells were harvested and RNA was extracted using the RNA Rapid Extraction Kit (Shanghai Yishan Biotechnology) with the following steps:
[0079] (1) Aspirate the culture medium and wash once with 1 ml of PBS.
[0080] (2) Add 500 μL of Lysis Buffer, pipette vigorously 10 times, transfer to an EP tube, and vortex for 10 seconds to fully lyse the cells.
[0081] (3) Add an equal volume of anhydrous ethanol to the lysed cells and mix thoroughly, then add the liquid to the binding column in the kit.
[0082] (4) Centrifuge at 4000 × g for one minute and discard the liquid.
[0083] (5) Use 600 μL of Wash Buffer, centrifuge at 12,000 × g for one minute, and discard the liquid.
[0084] (6) Pour the column once and centrifuge at 12,000 × g for one minute.
[0085] (7) Add 30 μL of RNA-free water and centrifuge at 12,000 × g for one minute to obtain RNA.
[0086] 4. Then reverse transcribe the extracted RNA into cDNA using a rapid reverse transcription kit (Shanghai Yishan Biotechnology) as follows:
[0087] (1) Take 100 ng-2 μg of total RNA, add 2 μL of DNase, add water to 16 μL, and mix gently by pipetting 5-10 times.
[0088] (2) Incubate at room temperature for 5 minutes and place on ice for later use.
[0089] (3) Then add 4 μL of 5×RT Mix to the above system.
[0090] (4) Pipette up and down 10 times to mix thoroughly.
[0091] (5) Incubate at 42°C for 15 minutes. Dilute 5-10 times and use as template for qPCR.
[0092] qPCR Primers:
[0093] Tgfb1:
[0094] Forward:5'-GACATTCGGGAAGCAG-3'(SEQ ID NO:4);
[0095] Reverse: 5'-CCACTCAGGCGTATCAG-3' (SEQ ID NO: 5).
[0096] Arg1:
[0097] Forword:5'-CATTGGCTTGCGAGACGTAGAC-3'(SEQ ID NO:6);
[0098] Reverse: 5'-GCTGAAGGTTCTCTCCATCACC-3' (SEQ ID NO: 7).
[0099] Ym1
[0100] Forward:5'-TCCTCAGAACCGTCAG-3'(SEQ ID NO:8);
[0101] Reverse: 5'-GAGTAGCAGCCTTGGA-3' (SEQ ID NO: 9).
[0102] Fizz1
[0103] Forward:5'-GAACTTCTTGCCAATCC-3'(SEQ ID NO:10);
[0104] Reverse: 5'-CCAGTAGCAGTCATCCC-3' (SEQ ID NO: 11).
[0105] GAPDH
[0106] Forward: 5'-CAGTGGCAAAGTGGAGATTGTTG-3' (SEQ ID NO: 12);
[0107] Reverse: 5'-CTCGCTCCTGGAAGATGGTGAT-3' (SEQ ID NO: 13).
[0108] Design qPCR primers for mouse Arg1, Tgfb1, Ym1, Fizz1, and mouse GAPDH. Use the cDNA obtained by reverse transcription as a template for qPCR. The qPCR system used is: 10 μL KAPA enzyme, 200 nM primers, 50 ng template, and 8 μL water.
[0109] The results showed that the peptide Pep2-PG could reduce the mRNA levels of Arg1, Tgfb1, Ym1, and Fizz1, indicating that Pep2-PG inhibited the profibrotic phenotype of macrophages. The results are shown in Table 4.
[0110] Table 4 Peptide Pep2-PG reduces the mRNA levels of Arg1, Tgfb1, Ym1, and Fizz1
[0111] Gene name Control peptide Pep2-PG P-value Arg1 1.067±0.178 0.283±0.104 0.00576 Tgfb1 1.147±0.104 0.217±0.074 0.00050 Ym1 0.853±0.104 0.240±0.061 0.00198 Fizz1 1.003±0.0939 0.370±0.113 0.00367
[0112] Example 7: Verification of the anti-pulmonary fibrosis effect of Pep2-PG using an animal model of pulmonary fibrosis
[0113] 7.1 The animal model prepared in Example 1 was divided into groups and administered 10 days after modeling. The grouping and administration are shown in Table 5 (ip means intraperitoneal injection):
[0114] Table 5 Grouping and drug administration of pulmonary fibrosis animal model after modeling
[0115]
[0116] 7.2 Flow cytometry detection of the expression of CD206, a marker gene for the profibrotic phenotype in alveolar macrophages of mice with bleomycin-induced pulmonary fibrosis
[0117] Mouse alveolar macrophages were isolated from bronchoalveolar lavage fluid. The alveolar lavage fluid was centrifuged at 300g for 15 minutes, and then the cells were resuspended and cultured with RPMI 1640 medium containing 10% serum. After 45 minutes, the non-adherent cells were discarded and the adherent alveolar macrophages were gently scraped off. After centrifugation at 2000rpm for 5 minutes, the cells were resuspended in flow cytometry buffer. After adding CD16 / 32 to block Fc receptors at room temperature for 5-10 minutes, Percp / cy5.5 anti-mouse CD45, APC anti-mouse F4 / 80, and FITC anti-mouse CD206 were added, and the cells were washed three times with PBS and then put on the machine (BD FACSVerse). The flow data were analyzed using FCS Express 6 software.
[0118] The results showed (Table 6) that the peptide Pep2-PG could significantly reduce the expression of macrophage CD206 and inhibit the profibrotic phenotype of macrophages.
[0119] Table 6 Peptide Pep2-PG reduces the expression of CD206 in alveolar macrophages
[0120]
[0121]
[0122] 7.3 Evaluation of lung function in mice with pulmonary fibrosis
[0123] Lung function is the gold standard for clinical detection of pulmonary fibrosis in patients. A decline in lung function is often accompanied by an increase in fibrosis, while an improvement in lung function often also represents the recovery of lung tissue structure.
[0124] The pulmonary fibrosis model mice obtained in Example 1 were anesthetized with sodium pentobarbital (45 mg / kg, ip), and pulmonary function was tested using the Flexivent small animal pulmonary function instrument. The detection method was TLC, SnapShots (for the detection method, please refer to: Lv X, Wang X, Li K, et al. Rupatadine Protects against Pulmonary Fibrosis by Attenuating PAF-Mediated Senescence in Rodents [J]. PloS one, 2013, 8 (7): e68631.).
[0125] The test results are shown in Tables 7-10, where Table 7 shows the deep inspiratory volume, Table 8 shows the dynamic resistance, Table 9 shows the dynamic elasticity, and Table 10 shows the dynamic compliance. As can be seen from Tables 7-10, compared with the sham operation group, the deep inspiratory volume of mice with pulmonary fibrosis induced by bleomycin was significantly reduced, the dynamic resistance and dynamic elasticity of the lungs increased, and the compliance was significantly reduced. After Pep2-PG treatment, lung function was significantly restored.
[0126] Table 7 Peptides increase deep inspiratory capacity in mice with pulmonary fibrosis
[0127] serial number Group Deep inspiratory volume (ml) P-value A Sham operation group 0.897±0.04656 B Model Group 0.337±0.06982 0.00003(A vs B) C Pep2-PG administration group 0.644±0.00256 0.00257(B vs C)
[0128] Table 8 Peptides reduce dynamic lung resistance in mice with pulmonary fibrosis
[0129] serial number Group <![CDATA[Dynamic resistance (cmH 2 O.s / ml)]]> P-value A Sham operation group 0.848±0.0904 B Model Group 2.280±0.493 0.00258(A vs B) C Pep2-PG administration group 1.182±0.188 0.01129(B vs C)
[0130] Table 9 Peptides reduce dynamic elasticity of lungs in mice with pulmonary fibrosis
[0131] serial number Group <![CDATA[Dynamic elasticity (cmH 2 O / ml)]]> P-value A Sham operation group 21.475±4.886 B Model Group 79.550±6.367 0.00002(A vs B) C Pep2-PG administration group 44.2±11.439 0.00341(B vs C)
[0132] Table 10 Peptides increase lung compliance in mice with pulmonary fibrosis
[0133] serial number Group <![CDATA[Compliance (cmH 2 O / ml)]]> P-value A Sham operation group 0.039±0.00274 B Model Group 0.0223±0.00487 0.00203(A vs B) C Pep2-PG administration group 0.0325±0.00391 0.02937(B vs C)
[0134] 7.4 Sirius Red Special Staining Pathological Imaging Analysis
[0135] Sirius red can specifically stain fibrotic collagen and is a special staining method commonly used for tissue sections.
[0136] The right lower lobe lung tissue of the animal was obtained, fixed with 4% paraformaldehyde and embedded in paraffin. The largest cross-sectional slice of the wax block of the embedded lung tissue was sliced and stained with Sirius red to observe the fibrosis. The high-definition color pathology image analysis system SpotAdvanced 3.0 was used to obtain high-definition Sirius red special staining pathology images (200 times), and the results are shown in Figure 2. Image-Pro Plus5.1 was used to measure the collagen staining area and lung tissue area under the field of view after Sirius red staining in each field of view. The relative content of collagen was expressed by the staining area and the ratio of the staining area to the lung tissue area in the field of view. In the bleomycin-induced pulmonary fibrosis experiment, 10 specimens were analyzed in each group, and 6 fields of view were randomly selected from each specimen. The mean value represented the relative content and expression intensity of collagen tissue in the lung tissue of an animal. The "absolute area of collagen under the field of view" of each group was compared by parametric analysis of variance. The results are shown in Table 11. After administration of bleomycin, obvious collagen accumulation appeared in the lungs of mice. Administration of Pep2-PG can reduce the lung collagen accumulation caused by bleomycin.
[0137] Table 11 Pep2-PG can reduce lung collagen accumulation caused by bleomycin
[0138] serial number Group Collagen area (IOD×10000) P-value A Sham operation group 4.15±0.634 B Model Group 10.875±1.161 0.00012(A vs B) C Pep2-PG administration group 5.575±1.126 0.00129(B vs C)
[0139] 7.5 Determination of Hydroxyproline Content in Mice with Pulmonary Fibrosis
[0140] Hydroxyproline accounts for 13.4% of collagen, a very small amount of elastin, and does not exist in other proteins. Therefore, the content of collagen is detected by hydroxyproline. The content of hydroxyproline in the whole left lung of the animal is detected to evaluate the condition of pulmonary fibrosis. The specific method is as follows: Take all the left lung lobes of the model animal prepared in Example 1, record the wet weight, prepare 10% tissue homogenate with physiological saline ultrasonic homogenate, take about 150 μl The homogenate supernatant was added with 500 μl of alkaline hydrolysis solution, vortexed and mixed, and then treated with alkaline hydrolysis at 120 degrees and 0.1 Kpa for 40 minutes (the method was slightly modified according to the kit instructions of Nanjing Jiancheng Bioengineering Technology Co., Ltd.), the pH value was adjusted to constant volume, and the supernatant was taken after activated carbon treatment. Hydroxyproline was determined according to the instructions (chloramine T method). The results are shown in Table 12. It can be seen from Table 12 that compared with the sham operation group, the hydroxyproline content and its significance in the model group increased, indicating that the pathological changes of fibrosis were serious. Pep2-PG administration can significantly reduce the content of hydroxyproline in the lungs of fibrotic mice.
[0141] Table 12 Peptides reduce hydroxyproline content in lung tissue of mice with pulmonary fibrosis
[0142] serial number Group Hydroxyproline content (g / mg protein) P-value A Sham operation group 0.523±0.0726 B Model Group 0.86±0.172 0.02025(A vs B) C Pep2-PG administration group 0.588±0.054 0.03962(B vs C)
[0143] In this experiment, through pathological examination, pathological imaging and other means of analysis, it was found that Pep2-PG can significantly inhibit bleomycin-induced lung fibrosis; significantly reduce the content of hydroxyproline and collagen in the lung tissue of mice with pulmonary fibrosis; and significantly improve the lung function of mice with pulmonary fibrosis. The above experimental results prove that Pep2-PG has excellent therapeutic prospects in pulmonary fibrosis.
[0144] The results of the above examples show that the polypeptide of the present invention has a significant effect in resisting pulmonary fibrosis and can be used as an active ingredient in the preparation of drugs against pulmonary fibrosis.
[0145] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention. Sequence Listing <110> Institute of Materia Medica, Chinese Academy of Medical Sciences <120> Polypeptide for targeted inhibition of TRIB3 and its use <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 12 <212> PRT <213> Human <400> 1 Glu Thr Val Tyr Arg Val Ala Arg His Tyr Ser Arg 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <400> 2 His Leu Tyr Val Ser Pro Trp 1 5
Claims
1. Use of polypeptides that can specifically bind to TRIB3 and their polypeptide derivatives in the preparation of drugs for treating pulmonary fibrosis; The amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO: 1; the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide with a cell-penetrating peptide; The cell-penetrating peptide has an amino acid sequence as shown in SEQ ID NO:
2.
2. The use according to claim 1, characterized in that The N-terminus or C-terminus of the polypeptide is connected to a cell-penetrating peptide to obtain the chimeric peptide.
3. The use according to claim 1, characterized in that The pulmonary fibrosis includes primary pulmonary fibrosis or secondary pulmonary fibrosis.
4. The use according to claim 1, characterized in that The pulmonary fibrosis includes drug-induced pulmonary fibrosis.
5. The use according to claim 4, characterized in that The drug-induced pulmonary fibrosis is drug-induced pulmonary fibrosis caused by bleomycin.
